Efficacy and safety of rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome: Rationale and design of the Trial on Rivaroxaban in AntiPhospholipid Syndrome (TRAPS) trial
Restricted accessResearch articleFirst published online March, 2016
Efficacy and safety of rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome: Rationale and design of the Trial on Rivaroxaban in AntiPhospholipid Syndrome (TRAPS) trial
New oral anticoagulants may simplify long-term therapy in conditions requiring anticoagulation. Rivaroxaban is a direct factor Xa inhibitor that has been extensively studied and is now approved for the prevention and therapy of a number of thromboembolic conditions.
Objective and methods
This is a multicentre, randomized, open-label, study that will evaluate if Rivaroxaban 20 mg od (or 15 mg od in patients with moderate renal insufficiency) is non-inferior to warfarin (INR target 2.5), for the prevention of thromboembolic events, major bleeding and death in high risk (triple positive) patients with antiphospholipid syndrome. Secondary endpoints will assess the incidence of any individual component of the composite end point. An external adjudication committee will evaluate all suspected outcome events. This will be a unique trial, as it will enrol the biggest homogenous cohort of high risk APS individuals.
Conclusion
The methods and the study design should be appropriate to achieve study results that are both scientifically valid and relevant to clinical practice.
MiyakisSLockshinMDAtsumiT. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost2006; 4: 295–306.
2.
PierangeliSSde GrootPGDlottJ. ‘Criteria' aPL tests: report of a task force and preconference workshop at the 13th International Congress on Antiphospholipid Antibodies, Galveston, Texas, April 2010. Lupus2011; 20: 182–190.
3.
LeeEYLeeCKLeeTH. Does the anti-beta2-glycoprotein I antibody provide additional information in patients with thrombosis?Thromb Res2003; 111: 29–32.
4.
PengoVBiasioloAPegoraroCCucchiniUNoventaFIlicetoS. Antibody profiles for the diagnosis of antiphospholipid syndrome. Thromb Haemost2005; 93: 1147–1152.
5.
SailerTZoghlamiCKurzC. Anti-beta2-glycoprotein I antibodies are associated with pregnancy loss in women with the lupus anticoagulant. Thromb Haemost2006; 95: 796–801.
6.
Zoghlami-RintelenCVormittagRSailerT. The presence of IgG antibodies against beta2-glycoprotein I predicts the risk of thrombosis in patients with the lupus anticoagulant. J Thromb Haemost2005; 3: 1160–1165.
7.
RuffattiATonelloMCavazzanaABagatellaPPengoV. Laboratory classification categories and pregnancy outcome in patients with primary antiphospholipid syndrome prescribed antithrombotic therapy. Thromb Res2009; 123: 482–287.
8.
PengoVRuffattiATonelloM. Antiphospholipid syndrome: Antibodies to Domain 1 of beta2-glycoprotein 1 correctly classify patients at risk. J Thromb Haemost2015; 13: 782–787.
9.
PengoVRuffattiALegnaniC. Clinical course of high-risk patients diagnosed with antiphospholipid syndrome. J Thromb Haemost2010; 8: 237–242.
10.
CrowtherMAGinsbergJSJulianJ. A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome. New Engl J Med2003; 349: 1133–1138.
11.
FinazziGMarchioliRBrancaccioV. A randomized clinical trial of high-intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS). J Thromb Haemost2005; 3: 848–853.
12.
InvestigatorsEBauersachsRBerkowitzSD. Oral rivaroxaban for symptomatic venous thromboembolism. New Engl J Med2010; 363: 2499–2510.
13.
PatelMRMahaffeyKWGargJ. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. New Engl J Med2011; 365: 883–891.
14.
MegaJLBraunwaldEWiviottSD. Rivaroxaban in patients with a recent acute coronary syndrome. New Engl J Med2012; 366: 9–19.
15.
HarrisPATaylorRThielkeRPayneJGonzalezNCondeJG. Research electronic data capture (REDCap) – a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Informatics2009; 42: 377–381.
16.
HeidbuchelHVerhammePAlingsM. EHRA practical guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation: executive summary. Eur Heart J2013; 34: 2094–2106.
17.
InvestigatorsE-PBullerHRPrinsMH. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. New Engl J Med2012; 366: 1287–1297.
18.
HankeyGJPatelMRStevensSR. Rivaroxaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of ROCKET AF. Lancet Neurol2012; 11: 315–322.
19.
Ruiz-IrastorzaGCuadradoMJRuiz-ArruzaI. Evidence-based recommendations for the prevention and long-term management of thrombosis in antiphospholipid antibody-positive patients: report of a task force at the 13th International Congress on antiphospholipid antibodies. Lupus2011; 20: 206–218.
20.
KhamashtaMACuadradoMJMujicFTaubNAHuntBJHughesGR. The management of thrombosis in the antiphospholipid-antibody syndrome. New Engl J Med1995; 332: 993–997.
21.
PengoVBiasioloAPegoraroC. A simple scheme to initiate oral anticoagulant treatment in outpatients with nonrheumatic atrial fibrillation. Am J Cardiol2001; 88: 1214–1216.
22.
PengoVCucchiniUDenasG. Standardized low-molecular-weight heparin bridging regimen in outpatients on oral anticoagulants undergoing invasive procedure or surgery: an inception cohort management study. Circulation2009; 119: 2920–2927.
23.
LevineSRBreyRLTilleyBC. Antiphospholipid antibodies and subsequent thrombo-occlusive events in patients with ischemic stroke. JAMA2004; 291: 576–584.
24.
PengoVRuffattiADel RossT. Confirmation of initial antiphospholipid antibody positivity depends on the antiphospholipid antibody profile. J Thromb Haemost2013; 11: 1527–1531.
